Medtronic plc (MDT)
| Previous close | 79.19 |
| Open | 79.25 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 1000 |
| Day's range | 79.28 - 79.64 |
| 52-week range | 68.84 - 92.02 |
| Volume | |
| Avg. volume | 6,383,474 |
| Market cap | 105.641B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 25.26 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.76 (3.49%) |
| Ex-dividend date | 21 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
Americans favor quality over quantity in pursuit of longevity
Americans overwhelmingly say that when they think about longevity, it's more than just living longer—it's about living their healthiest, best lives. While most want to live to 90—well past the average U.S. life expectancy of 77.5 years—nearly two-thirds (66%) would choose a shorter, healthier life over a longer one with health issues. These findings, from a survey conducted by global healthcare technology leader Medtronic with Morning Consult, highlight a gap between U.S. adults' desire to live
- PR Newswire
Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.
- PR Newswire
The Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial fibrillation (AFib). Interim findings from the first-in-human Sphere-360 study were presented as a late-breaking clinical trial at the European Heart Rhythm Association (EHRA) 2024 Annual Meeting.
